St. John's, Canada

Nancy Merner




Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nancy Merner: Innovator in Cardiomyopathy Diagnostics

Introduction

Nancy Merner is a prominent inventor based in St. John's, Canada. She has made significant contributions to the field of cardiomyopathy diagnostics, holding 2 patents that focus on innovative methods for diagnosing and treating this serious condition. Her work is particularly relevant in the context of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C).

Latest Patents

Merner's latest patents include a diagnostic test for cardiomyopathy. This invention describes methods and compositions related to diagnosing and treating cardiomyopathy, specifically focusing on ARVD/C. The patent outlines methods for screening, diagnosing, or detecting a risk of developing ARVD/C by identifying the presence of a transmembrane protein 43 (TMEM43) disease-associated variant in a subject's sample. The presence of this variant indicates that the subject has ARVD/C or an increased risk of developing the condition compared to individuals with the wild type TMEM43.

Career Highlights

Throughout her career, Nancy Merner has worked with notable organizations, including Genesis Group Inc. and Memorial University of Newfoundland. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community significantly.

Collaborations

Some of her notable coworkers include Terry-Lynn Young and Kathy Hodgkinson. Their collaboration has likely enriched the research environment and fostered innovative solutions in the field of cardiomyopathy.

Conclusion

Nancy Merner's contributions to cardiomyopathy diagnostics through her patents and collaborations highlight her role as an influential inventor in the medical field. Her work continues to pave the way for advancements in diagnosing and treating this critical condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…